Hemophilia: a bedside monitor and app to track FVIII and emicizumab
Official title: Hemophilia Point-of-Care Monitoring Device and App
Funded at DNA Medicine Institute · NIH-11367348 · Data updated 2026-11-12
A new point-of-care device and app help people with hemophilia A quickly measure FVIII activity and emicizumab levels at home or in clinics.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | DNA Medicine Institute NIH-funded |
| Lab location | 1 site (Cambridge, UNITED STATES) |
| Project start | September 10, 2020 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44HL151147-05 |
| Project ID | NIH-11367348 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with hemophilia A who require FVIII or emicizumab monitoring and have access to point-of-care testing.
✕Less likely to help
Patients without access to point-of-care settings or those not requiring FVIII/emicizumab monitoring may not benefit.
What this research studies
This project aims to bring a fast, 15-minute test for Factor VIII activity and emicizumab to patients with hemophilia A. Building on a CE-marked assay and a microfluidic cartridge system, the team will develop a user-friendly device and companion app that provide rapid results and support treatment decisions. The work includes design controls to meet regulatory standards and pilot production for real-world use. If successful, patients could benefit from timely dosing information during bleeds, surgeries, or routine care.
Why it matters
Potential benefit: Potential to empower patients with rapid, reliable testing to guide treatment decisions and reduce bleeding risks.
How similar studies have gone: Previous assays and device concepts exist, but this plan aims for CE-mark/FDA-cleared POC integration with a dedicated app, representing a novel combination that could enhance care.
Where this research is happening
-
DNA Medicine Institute
Cambridge, United States Active
Researchers
- Principal investigator: Chan, Eugene Yan-Ho — DNA Medicine Institute
- Study coordinator: Chan, Eugene Yan-Ho
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.